Category Archives: Intellectual Property

Eligibility Cannot be Raised in IPR Appeal

Neptune Generics v. Eli Lilly (Fed. Cir. 2019)Mylan Labs v. Eli Lilly (Fed. Cir. 2019) This appeal combines twelve different inter partes review (IPR) proceedings. In each case, the PTAB Board sided with the patentee — holding that the claims of … Continue reading

Posted in Intellectual Property | Tagged , , , | Leave a comment

Content Moderation is Broken. Let Us Count the Ways.

Social media platforms regularly engage in “content moderation”—the depublication, downranking, and sometimes outright censorship of information and/or user accounts from social media and other digital platforms, usually based on an alleged violation of a platform’s “community standards” policy. In recent … Continue reading

Posted in Intellectual Property | Tagged , , , , | Leave a comment

Accelerating Generic Entry: A Proven Solution to the Problem of Prescription Drug Pricing

High prescription drug prices and their impact on costs borne by the government in Medicaid, Medicare Part D and other federal programs, is a front burner topic in Washington. The President has committed to reducing the price of prescription drugs, … Continue reading

Posted in Intellectual Property | Tagged , , , , , , , , | Leave a comment

JMLS Program on ITC Practice

The John Marshall Law School Center for Intellectual Property, Information & Privacy Law will be hosting an IP Executive Seminar on "ITC Practice—What Every IP Attorney and In-House Counsel Should Know" from 9:00 am to 4:30 pm on May 10, … Continue reading

Posted in Intellectual Property | Tagged , , | Leave a comment

The Future of Patents on Genetically Modified Organisms in India

Earlier this year, the Supreme Court of India set aside an order of the division bench of the Delhi High Court that revoked a patent granted on genetically modified cotton, holding that the single bench of the High Court should … Continue reading

Posted in Intellectual Property | Tagged , , , | Leave a comment